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Scar-free healing
Mending wounds quickly while keeping them scar-free is not 
an impossible task. Mori et al. (page 43) find that shutting down 
a protein called osteopontin does the trick.
Scars form when the inflammatory response that protects 
skin wounds against invading microbes induces the release of 
chemokines, which recruit fibroblasts. These cells then 
generate swathes of collagen to provide a new matrix for 
epithelial cells to close the wound. But all that new collagen 
stands out from the surrounding skin. It is also more than a 
cosmetic blight: scarring in injured organs can cause organ 
damage when the new collagen hardens.
Mori et al. previously found that injuries healed faster, 
without scarring, in knockout mice that lack neutrophils, macrophages, and mast cells. These mice 
are unable to mount a normal inflammatory response and fail to recruit fibroblasts to the wound. 
The mice had lower levels of osteopontin, a structural protein required for bone formation, which is 
secreted by the wound fibroblasts during inflammation.
The group now finds that suppressing osteopontin alone in healing wounds accelerates repair 
and reduces scarring. The researchers treated skin wounds on mice with a gel containing osteopontin 
antisense DNA. The resulting reduction in osteopontin levels increased the regeneration of blood 
vessels around the wound and sped up tissue reconstruction. These wounds had a sparser collagen 
matrix that might allow blood vessels to grow unimpeded.
Treated wounds also contained fewer macrophages, which the authors found normally amplify 
osteopontin production and inflammation via cytokine secretion. The team has yet to test whether this 
reduction in macrophage numbers increases the risk of infection.
How osteopontin beefs up scar tissue is still unclear. The collagen matrix within the gel-treated 
wounds was composed of thinner collagen fibrils, suggesting that osteopontin somehow directs either 
the synthesis or assembly of collagen during the repair process. 
Try as it might to pull itself forward, 
an immune cell will go nowhere unless 
a myosin also pushes it from behind, 
report Morin et al. (page 195).
An immune cell holds onto the un-
derlying matrix or another cell with 
the help of membrane receptors called 
integrins. When the cell receives a 
chemokine signal, the integrins change 
shape, allowing them to grab onto 
their ligands on target cells. Using the 
traction provided by these integrin 
links, the now sticky cell elongates a 
leading edge in the direction of migra-
tion and is trailed by a uropod—the 
back end of the cell.
The cell moves ahead when the inte-
grins deactivate and the integrin-ligand 
bonds in the uropod are broken. The 
forces that unstick the uropod to allow 
forward propulsion are unknown.
Morin et al. hunted for these forces 
by looking for proteins that bind to a 
T cell integrin called LFA-1 in cells 
that are getting ready to move. They 
found a nonmuscle form of the myo-
sin motor called MyH9, which is 
known to be required for immune cell 
migration. Images and videos showed 
that this actin-based motor docked 
with LFA-1 in the uropod but not in 
the leading edge.
Cells that were treated with a myo-
sin inhibitor or a myosin-specific siRNA 
froze into comet shapes with extended 
uropods that failed to detach. The motor’s 
action thus seems to break LFA-1’s 
hold on its ligand.
Even without the myosin, the uro-
pod integrins were already in an inactive 
form, as shown by their failure to bind 
antibodies specific for active integrins. 
Clusters of these inactive integrins, 
however, still formed weak bonds with 
their ligands. The positioning of the 
myosin near these weak attachments 
might allow the motor to pop them apart 
via actin contraction.
The mechanism that inactivates in-
tegrins in the uropod is not yet known. 
It is possible that integrins deactivate as 
they drift farther from the activating 
chemokine signal at the cell’s leading edge.
How the myosin distinguishes be-
tween active and inactive LFA-1 is another 
question that still needs an answer. 
Helping lymphocytes to move on
Treating skin wounds (blue) with osteopontin antisense DNA (top) 
reduces the size of scars (area between arrows).
Cells elongate but are unable to detach their 
tails when the MyH9 myosin is blocked.